# Clene Inc.: financial statements, quarterly CLNN · Nasdaq · CIK 1822791 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/clnn.md) · [Financials](/companies/clnn/financials.md) · [Filings](/companies/clnn/filings.md) · [Insiders](/companies/clnn/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clnn/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001437749-24-034663.md) | [0.2 d](/filings/0001437749-25-008956.md) | [0.1](/filings/0001437749-25-014918.md) | [0.1](/filings/0001437749-25-026679.md) | [0.1](/filings/0001437749-25-034613.md) | [0.1 d](/filings/0001437749-26-008502.md) | [0.1](/filings/0001437749-26-016878.md) | [0.0](/filings/0001437749-26-027828.md) | [0.0](/filings/0001437749-25-034613.md) | [0.1 d](/filings/0001437749-26-008502.md) | [0.0](/filings/0001437749-26-016878.md) | [0.1](/filings/0001437749-26-027828.md) | | Cost of revenue | $m | [0.0](/filings/0001437749-24-034663.md) | [0.0 d](/filings/0001437749-25-008956.md) | [0.0](/filings/0001437749-25-014918.md) | [0.0](/filings/0001437749-25-026679.md) | [0.0](/filings/0001437749-25-034613.md) | [0.0 d](/filings/0001437749-26-008502.md) | [0.0](/filings/0001437749-26-016878.md) | [0.0](/filings/0001437749-26-027828.md) | [0.0](/filings/0001437749-25-034613.md) | [0.0 d](/filings/0001437749-26-008502.md) | [0.0](/filings/0001437749-26-016878.md) | [0.0](/filings/0001437749-26-027828.md) | | Research and development | $m | [6.0](/filings/0001437749-24-034663.md) | [6.7 d](/filings/0001437749-25-008956.md) | [5.9](/filings/0001437749-25-014918.md) | [4.2](/filings/0001437749-25-026679.md) | [4.5](/filings/0001437749-25-034613.md) | [5.6 d](/filings/0001437749-26-008502.md) | [1.5](/filings/0001437749-26-016878.md) | [3.5](/filings/0001437749-26-027828.md) | [3.5](/filings/0001437749-25-034613.md) | [5.5 d](/filings/0001437749-26-008502.md) | [0.3](/filings/0001437749-26-016878.md) | [3.5](/filings/0001437749-26-027828.md) | | Operating income | $m | [(9.5)](/filings/0001437749-24-034663.md) | [(9.9) d](/filings/0001437749-25-008956.md) | [(9.2)](/filings/0001437749-25-014918.md) | [(7.4)](/filings/0001437749-25-026679.md) | [(7.8)](/filings/0001437749-25-034613.md) | [(8.7) d](/filings/0001437749-26-008502.md) | [(4.1)](/filings/0001437749-26-016878.md) | [(5.9)](/filings/0001437749-26-027828.md) | [(5.6)](/filings/0001437749-25-034613.md) | [(7.5) d](/filings/0001437749-26-008502.md) | [(2.1)](/filings/0001437749-26-016878.md) | [(5.3)](/filings/0001437749-26-027828.md) | | Interest expense | $m | [1.2](/filings/0001437749-23-030487.md) | [1.2 d](/filings/0001437749-24-007542.md) | [1.2](/filings/0001437749-24-015209.md) | [1.3](/filings/0001437749-25-026679.md) | [1.0](/filings/0001437749-25-034613.md) | [0.5 d](/filings/0001437749-26-008502.md) | [0.6](/filings/0001437749-26-016878.md) | [0.7](/filings/0001437749-26-027828.md) | [0.6](/filings/0001437749-25-034613.md) | [0.7 d](/filings/0001437749-26-008502.md) | [0.8](/filings/0001437749-26-016878.md) | [0.7](/filings/0001437749-26-027828.md) | | Income tax | $m | [0.0](/filings/0001437749-24-034663.md) | [0.0 d](/filings/0001437749-25-008956.md) | [0.0](/filings/0001437749-25-014918.md) | [0.0](/filings/0001437749-25-026679.md) | [0.0](/filings/0001437749-25-034613.md) | [0.0 d](/filings/0001437749-26-008502.md) | [0.0](/filings/0001437749-26-016878.md) | [0.0](/filings/0001437749-26-027828.md) | [0.0](/filings/0001437749-25-034613.md) | [0.0 d](/filings/0001437749-26-008502.md) | [0.0](/filings/0001437749-26-016878.md) | [0.0](/filings/0001437749-26-027828.md) | | Net income | $m | [(2.4)](/filings/0001437749-24-034663.md) | [(10.2) d](/filings/0001437749-25-008956.md) | [(11.1)](/filings/0001437749-25-034613.md) | [(6.8)](/filings/0001437749-25-034613.md) | [(8.0)](/filings/0001437749-25-034613.md) | [(13.5) d](/filings/0001437749-26-008502.md) | [(0.8)](/filings/0001437749-26-027828.md) | [(7.4)](/filings/0001437749-26-027828.md) | [(8.8)](/filings/0001437749-25-034613.md) | [(9.2) d](/filings/0001437749-26-008502.md) | [(8.1)](/filings/0001437749-26-027828.md) | [(13.4)](/filings/0001437749-26-027828.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Basic EPS | $ per share | [(0.38)](/filings/0001437749-24-034663.md) | not reported | [(1.73)](/filings/0001437749-25-014918.md) | [(1.06)](/filings/0001437749-25-026679.md) | [(1.22)](/filings/0001437749-25-034613.md) | not reported | [(0.09)](/filings/0001437749-26-016878.md) | [(0.78)](/filings/0001437749-26-027828.md) | [(0.85)](/filings/0001437749-25-034613.md) | not reported | [(0.69)](/filings/0001437749-26-016878.md) | [(1.08)](/filings/0001437749-26-027828.md) | - Revenue: us-gaap:Revenues - Cost of revenue: us-gaap:CostOfRevenue - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: not reported - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [42.1](/filings/0001437749-23-030487.md) | [28.8](/filings/0001437749-25-008956.md) | [21.7](/filings/0001437749-24-015209.md) | [21.7](/filings/0001437749-24-025014.md) | [14.6](/filings/0001437749-24-034663.md) | [12.2](/filings/0001437749-26-008502.md) | [9.8](/filings/0001437749-25-014918.md) | [7.3](/filings/0001437749-25-026679.md) | [7.9](/filings/0001437749-25-034613.md) | [5.2](/filings/0001437749-26-027828.md) | [5.9](/filings/0001437749-26-016878.md) | [9.7](/filings/0001437749-26-027828.md) | | Current assets | $m | [46.4](/filings/0001437749-23-030487.md) | [38.9](/filings/0001437749-25-008956.md) | [32.1](/filings/0001437749-24-015209.md) | [27.9](/filings/0001437749-24-025014.md) | [19.7](/filings/0001437749-24-034663.md) | [16.2](/filings/0001437749-26-008502.md) | [14.7](/filings/0001437749-25-014918.md) | [12.0](/filings/0001437749-25-026679.md) | [12.7](/filings/0001437749-25-034613.md) | [9.0](/filings/0001437749-26-027828.md) | [13.0](/filings/0001437749-26-016878.md) | [14.9](/filings/0001437749-26-027828.md) | | Total assets | $m | [60.4](/filings/0001437749-23-030487.md) | [52.3](/filings/0001437749-25-008956.md) | [45.1](/filings/0001437749-24-015209.md) | [40.3](/filings/0001437749-24-025014.md) | [31.6](/filings/0001437749-24-034663.md) | [27.3](/filings/0001437749-26-008502.md) | [25.3](/filings/0001437749-25-014918.md) | [22.1](/filings/0001437749-25-026679.md) | [22.3](/filings/0001437749-25-034613.md) | [18.1](/filings/0001437749-26-027828.md) | [21.7](/filings/0001437749-26-016878.md) | [23.0](/filings/0001437749-26-027828.md) | | Current liabilities | $m | [15.3](/filings/0001437749-23-030487.md) | [25.3](/filings/0001437749-25-008956.md) | [26.2](/filings/0001437749-24-015209.md) | [28.1](/filings/0001437749-24-025014.md) | [23.8](/filings/0001437749-24-034663.md) | [10.3](/filings/0001437749-26-008502.md) | [10.8](/filings/0001437749-25-014918.md) | [7.6](/filings/0001437749-25-026679.md) | [8.3](/filings/0001437749-25-034613.md) | [10.8](/filings/0001437749-26-027828.md) | [6.7](/filings/0001437749-26-016878.md) | [4.9](/filings/0001437749-26-027828.md) | | Total liabilities | $m | [39.0](/filings/0001437749-23-030487.md) | [39.0](/filings/0001437749-25-008956.md) | [40.8](/filings/0001437749-24-015209.md) | [40.8](/filings/0001437749-24-025014.md) | [35.7](/filings/0001437749-24-034663.md) | [36.2](/filings/0001437749-26-008502.md) | [30.3](/filings/0001437749-25-014918.md) | [30.7](/filings/0001437749-25-026679.md) | [34.7](/filings/0001437749-25-034613.md) | [35.7](/filings/0001437749-26-027828.md) | [40.5](/filings/0001437749-26-016878.md) | [47.8](/filings/0001437749-26-027828.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | [16.6](/filings/0001437749-25-014918.md) | [16.5](/filings/0001437749-25-026679.md) | [17.9](/filings/0001437749-25-034613.md) | [17.8](/filings/0001437749-26-008502.md) | [17.7](/filings/0001437749-26-016878.md) | [17.6](/filings/0001437749-26-027828.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [21.4](/filings/0001437749-24-034663.md) | [13.4](/filings/0001437749-26-008502.md) | [4.3](/filings/0001437749-25-034613.md) | [(0.5)](/filings/0001437749-25-034613.md) | [(4.1)](/filings/0001437749-25-034613.md) | [(8.9)](/filings/0001437749-26-027828.md) | [(5.0)](/filings/0001437749-26-027828.md) | [(8.6)](/filings/0001437749-26-027828.md) | [(12.4)](/filings/0001437749-25-034613.md) | [(17.6)](/filings/0001437749-26-027828.md) | [(18.8)](/filings/0001437749-26-027828.md) | [(24.8)](/filings/0001437749-26-027828.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(6,760) d](/filings/0001437749-24-034663.md) | [(7,172) d](/filings/0001437749-25-008956.md) | [(7,082)](/filings/0001437749-25-014918.md) | [(6,356) d](/filings/0001437749-25-026679.md) | [(3,023) d](/filings/0001437749-25-034613.md) | [(4,865) d](/filings/0001437749-26-008502.md) | [(5,011)](/filings/0001437749-26-016878.md) | [(4,744) d](/filings/0001437749-26-027828.md) | [(3,992) d](/filings/0001437749-25-034613.md) | [(4,799) d](/filings/0001437749-26-008502.md) | [(4,528)](/filings/0001437749-26-016878.md) | [(2,588) d](/filings/0001437749-26-027828.md) | | Capital expenditure | $k | [48.0 d](/filings/0001437749-24-034663.md) | [43.0 d](/filings/0001437749-25-008956.md) | [11.0](/filings/0001437749-25-014918.md) | [2.0 d](/filings/0001437749-25-026679.md) | [1.0 d](/filings/0001437749-25-034613.md) | [1.0 d](/filings/0001437749-26-008502.md) | [0.0](/filings/0001437749-25-014918.md) | [0.0 d](/filings/0001437749-26-027828.md) | [11.0 d](/filings/0001437749-25-034613.md) | [28.0 d](/filings/0001437749-26-008502.md) | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | period not labelled (2020-09-30) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [17.4](/filings/0001213900-21-057373.md) | [61.2](/filings/0000950170-22-017214.md) | [70.0](/filings/0000950170-22-022333.md) | [63.3](/filings/0000950170-22-017214.md) | [63.5](/filings/0000950170-22-022333.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 12,848,513 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-027828.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.